• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国 1997-2013 年艾滋病毒感染者治疗费用的上升。

Rising population cost for treating people living with HIV in the UK, 1997-2013.

机构信息

NPMS-HHC Coordinating and Analytic Centre, London, United Kingdom.

出版信息

PLoS One. 2010 Dec 30;5(12):e15677. doi: 10.1371/journal.pone.0015677.

DOI:10.1371/journal.pone.0015677
PMID:21209893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3012705/
Abstract

BACKGROUND

The number of people living with HIV (PLHIV) is increasing in the UK. This study estimated the annual population cost of providing HIV services in the UK, 1997-2006 and projected them 2007-2013.

METHODS

Annual cost of HIV treatment for PLHIV by stage of HIV infection and type of ART was calculated (UK pounds, 2006 prices). Population costs were derived by multiplying the number of PLHIV by their annual cost for 1997-2006 and projected 2007-2013.

RESULTS

Average annual treatment costs across all stages of HIV infection ranged from £17,034 in 1997 to £18,087 in 2006 for PLHIV on mono-therapy and from £27,649 in 1997 to £32,322 in 2006 for those on quadruple-or-more ART. The number of PLHIV using NHS services rose from 16,075 to 52,083 in 2006 and was projected to increase to 78,370 by 2013. Annual population cost rose from £104 million in 1997 to £483 million in 2006, with a projected annual cost between £721 and £758 million by 2013. When including community care costs, costs increased from £164 million in 1997, to £683 million in 2006 and between £1,019 and £1,065 million in 2013.

CONCLUSIONS

Increased number of PLHIV using NHS services resulted in rising UK population costs. Population costs are expected to continue to increase, partly due to PLHIV's longer survival on ART and the relative lack of success of HIV preventing programs. Where possible, the cost of HIV treatment and care needs to be reduced without reducing the quality of services, and prevention programs need to become more effective. While high income countries are struggling to meet these increasing costs, middle- and lower-income countries with larger epidemics are likely to find it even more difficult to meet these increasing demands, given that they have fewer resources.

摘要

背景

在英国,感染艾滋病毒的人数(PLHIV)正在增加。本研究估算了 1997-2006 年英国提供艾滋病毒服务的年度人口成本,并对 2007-2013 年的成本进行了预测。

方法

根据艾滋病毒感染阶段和抗逆转录病毒治疗(ART)类型,计算 PLHIV 的艾滋病毒治疗年度费用(1997-2006 年为英镑,2006 年价格)。人口成本是通过将 PLHIV 的数量乘以其在 1997-2006 年的年度成本和 2007-2013 年的预测成本得出的。

结果

在所有艾滋病毒感染阶段,使用单一疗法的 PLHIV 的平均年度治疗费用从 1997 年的 17034 英镑降至 2006 年的 18087 英镑,而使用四联或更多 ART 的 PLHIV 的费用从 1997 年的 27649 英镑降至 2006 年的 32322 英镑。使用国民保健服务的 PLHIV 人数从 1997 年的 16075 人增加到 2006 年的 52083 人,并预计到 2013 年将增加到 78370 人。1997 年的年度人口成本为 1.04 亿英镑,到 2006 年增至 4.83 亿英镑,预计到 2013 年每年将在 7.21 亿至 7.58 亿英镑之间。当包括社区护理费用时,成本从 1997 年的 1.64 亿英镑增加到 2006 年的 6.83 亿英镑,预计到 2013 年将在 10.19 亿至 10.65 亿英镑之间。

结论

使用国民保健服务的 PLHIV 人数增加导致英国人口成本上升。预计人口成本将继续增加,部分原因是 PLHIV 在接受 ART 治疗后存活时间延长,以及艾滋病毒预防计划相对缺乏成功。在可能的情况下,需要在不降低服务质量的情况下降低艾滋病毒治疗和护理成本,并使预防计划更加有效。当高收入国家正在努力应对这些不断增加的成本时,中低收入国家由于资源较少,可能更难以满足这些不断增长的需求,而这些国家的艾滋病毒流行规模更大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/ef6d0cf7e8e6/pone.0015677.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/23b1985b34ab/pone.0015677.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/b4a3a229a9a7/pone.0015677.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/76e2906665f2/pone.0015677.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/5907c940a2ba/pone.0015677.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/ef6d0cf7e8e6/pone.0015677.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/23b1985b34ab/pone.0015677.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/b4a3a229a9a7/pone.0015677.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/76e2906665f2/pone.0015677.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/5907c940a2ba/pone.0015677.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e6b/3012705/ef6d0cf7e8e6/pone.0015677.g005.jpg

相似文献

1
Rising population cost for treating people living with HIV in the UK, 1997-2013.英国 1997-2013 年艾滋病毒感染者治疗费用的上升。
PLoS One. 2010 Dec 30;5(12):e15677. doi: 10.1371/journal.pone.0015677.
2
Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom.在低流行率的高收入国家扩大艾滋病毒检测:英国的成本效益分析
PLoS One. 2014 Apr 24;9(4):e95735. doi: 10.1371/journal.pone.0095735. eCollection 2014.
3
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.英国 1996-2008 年早期获得 HIV 服务和开始 cART 的成本效益。
PLoS One. 2011;6(12):e27830. doi: 10.1371/journal.pone.0027830. Epub 2011 Dec 14.
4
Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006.英国 1996-2006 年一线基于 NNRTI 的高效抗逆转录病毒治疗方案早期治疗的成本效益。
PLoS One. 2011;6(5):e20200. doi: 10.1371/journal.pone.0020200. Epub 2011 May 25.
5
Long-term costs and health impact of continued global fund support for antiretroviral therapy.长期全球基金抗逆转录病毒治疗持续资助的成本和健康影响。
PLoS One. 2011;6(6):e21048. doi: 10.1371/journal.pone.0021048. Epub 2011 Jun 23.
6
Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start.基于抗逆转录病毒治疗的成本节约干预措施可能会抵消新患者的费用和更早的治疗开始。
HIV Med. 2014 Mar;15(3):165-74. doi: 10.1111/hiv.12097. Epub 2013 Oct 31.
7
Cost implications of HIV retesting for verification in Africa.在非洲,HIV 重新检测以进行确认的成本影响。
PLoS One. 2019 Jul 1;14(7):e0218936. doi: 10.1371/journal.pone.0218936. eCollection 2019.
8
Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.利用英国抗逆转录病毒药物价格对 MONET 试验进行成本效益分析。
Appl Health Econ Health Policy. 2011 Jul 1;9(4):217-23. doi: 10.2165/11592220-000000000-00000.
9
Can differentiated care models solve the crisis in HIV treatment financing? Analysis of prospects for 38 countries in sub-Saharan Africa.差异化护理模式能否解决艾滋病治疗资金危机?对撒哈拉以南非洲38个国家的前景分析。
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21648. doi: 10.7448/IAS.20.5.21648.
10
One world, one hope: the cost of providing antiretroviral therapy to all nations.同一个世界,同一个希望:为所有国家提供抗逆转录病毒疗法的成本。
AIDS. 1998 Nov 12;12(16):2203-9. doi: 10.1097/00002030-199816000-00016.

引用本文的文献

1
The efficiency of the EmERGE platform for medically stable people living with HIV in Portugal.EmERGE平台对葡萄牙医学状况稳定的HIV感染者的有效性。
Porto Biomed J. 2022 Oct 24;7(5):e191. doi: 10.1097/j.pbj.0000000000000191. eCollection 2022 Sep-Oct.
2
The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE.克罗地亚稳定期 HIV 感染者的护理成本和 EmERGE 的效率。
Croat Med J. 2021 Dec 31;62(6):542-552. doi: 10.3325/cmj.2021.62.542.
3
Auricular reconstruction: where are we now? A critical literature review.

本文引用的文献

1
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.男男性行为人群 HIV 预防的暴露前药物预防。
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.
2
Combination prevention: a deeper understanding of effective HIV prevention.联合预防:深入了解有效的艾滋病预防措施。
AIDS. 2010 Oct;24 Suppl 4:S70-80. doi: 10.1097/01.aids.0000390709.04255.fd.
3
Antiretroviral vaginal gel shows promise against HIV.抗逆转录病毒阴道凝胶有望对抗艾滋病毒。
耳廓重建:我们现在在哪里?一篇批判性文献综述。
Eur Arch Otorhinolaryngol. 2022 Feb;279(2):541-556. doi: 10.1007/s00405-021-06903-5. Epub 2021 Jun 2.
4
Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000-2020.全球和区域 50 岁及以上艾滋病毒感染者趋势:2000-2020 年的估计和预测。
PLoS One. 2018 Nov 29;13(11):e0207005. doi: 10.1371/journal.pone.0207005. eCollection 2018.
5
Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: A prospective hospital cohort study in Malawi.高 HIV 流行率住院患者的经济成本和与健康相关的生活质量结果:马拉维一项前瞻性医院队列研究。
PLoS One. 2018 Mar 15;13(3):e0192991. doi: 10.1371/journal.pone.0192991. eCollection 2018.
6
Effectiveness and cost-effectiveness of implementing HIV testing in primary care in East London: protocol for an interrupted time series analysis.在伦敦东部的初级保健中实施艾滋病毒检测的效果和成本效益:一项中断时间序列分析的研究方案。
BMJ Open. 2017 Dec 14;7(12):e018163. doi: 10.1136/bmjopen-2017-018163.
7
Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study.就诊延迟增加了HIV感染者非感染性合并症的风险和成本:一项意大利成本影响研究。
AIDS Res Ther. 2017 Feb 16;14(1):8. doi: 10.1186/s12981-016-0129-4.
8
Economic benefits of safety-engineered sharp devices in Belgium - a budget impact model.比利时安全工程锐器的经济效益——预算影响模型。
BMC Health Serv Res. 2013 Nov 25;13:489. doi: 10.1186/1472-6963-13-489.
9
Cost of noninfectious comorbidities in patients with HIV.艾滋病毒患者非传染性合并症的成本。
Clinicoecon Outcomes Res. 2013 Sep 23;5:481-8. doi: 10.2147/CEOR.S40607.
10
Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain.西班牙针对HIV-1病毒血症得到抑制的患者降低抗逆转录病毒治疗成本的抗逆转录病毒治疗转换策略
Clinicoecon Outcomes Res. 2013 May 23;5:215-21. doi: 10.2147/CEOR.S43662. Print 2013.
Lancet. 2010 Jul 31;376(9738):320. doi: 10.1016/s0140-6736(10)61123-3.
4
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.海地 HIV 感染成人的早期与标准抗逆转录病毒治疗。
N Engl J Med. 2010 Jul 15;363(3):257-65. doi: 10.1056/NEJMoa0910370.
5
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.加拿大不列颠哥伦比亚省高效抗逆转录病毒治疗覆盖率、人群病毒载量与每年新增 HIV 诊断病例的关联:一项基于人群的研究。
Lancet. 2010 Aug 14;376(9740):532-9. doi: 10.1016/S0140-6736(10)60936-1. Epub 2010 Jul 16.
6
Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis.美国未来 HIV 流行率、发病率和潜在感染人数的预估:多情景分析。
J Acquir Immune Defic Syndr. 2010 Oct;55(2):271-6. doi: 10.1097/QAI.0b013e3181e8f90c.
7
Economic evaluation of ART in resource-limited countries.资源有限国家的抗逆转录病毒治疗的经济评价。
Curr Opin HIV AIDS. 2010 May;5(3):225-31. doi: 10.1097/COH.0b013e3283384a9d.
8
Critical choices in financing the response to the global HIV/AIDS pandemic.全球艾滋病大流行应对资金筹措的关键选择。
Health Aff (Millwood). 2009 Nov-Dec;28(6):1591-605. doi: 10.1377/hlthaff.28.6.1591.
9
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
10
Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).英国不同高效抗逆转录病毒治疗方案的治疗效果及成本效益(1996 - 2002年)
Int J STD AIDS. 2008 May;19(5):297-304. doi: 10.1258/ijsa.2007.007236.